Pluri Inc. Overview
Pro stress-test →Pluri Inc. pioneered mass-scale cell expansion and biofarming, using a patented, proprietary 3D cell expansion platform to develop scalable, consistent and cost-efficient cell-based solutions. The company applies this platform across regenerative medicine, foodtech, agtech, aesthetics and Contract Development and Manufacturing Organization (CDMO) services, with the goal of addressing global challenges such as sustainable food production, healthcare and climate resilience.
Strategic Profile
Pro stress-test →With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges. Pluri is a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures.
Competitive Landscape
Pro stress-test →Pluri operates in the cell therapy and regenerative medicine space, competing against established players in immunotherapy, cell manufacturing, and biofarming. Key competitors include publicly-traded biotech companies focused on cell-based therapeutics and CDMO services, as well as emerging ventures in food-tech and agricultural biotech leveraging cellular agriculture technologies.
Industry Context
Pluri Inc. operates in Biotechnology - Cell Therapy & Regenerative Medicine.
Key facts
Founded: N/A · Headquarters: Haifa, Israel · Employees: N/A · Revenue: $1.3M · Market cap: $109.05M